These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 8819509

  • 1. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases.
    Sharif NA, Xu SX, Miller ST, Gamache DA, Yanni JM.
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1252-61. PubMed ID: 8819509
    [Abstract] [Full Text] [Related]

  • 2. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent.
    Yanni JM, Stephens DJ, Miller ST, Weimer LK, Graff G, Parnell D, Lang LS, Spellman JM, Brady MT, Gamache DA.
    J Ocul Pharmacol Ther; 1996 Sep; 12(4):389-400. PubMed ID: 8951675
    [Abstract] [Full Text] [Related]

  • 3. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis.
    Sharif NA, Xu SX, Yanni JM.
    J Ocul Pharmacol Ther; 1996 Sep; 12(4):401-7. PubMed ID: 8951676
    [Abstract] [Full Text] [Related]

  • 4. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells.
    Yanni JM, Miller ST, Gamache DA, Spellman JM, Xu S, Sharif NA.
    Ann Allergy Asthma Immunol; 1997 Dec; 79(6):541-5. PubMed ID: 9433371
    [Abstract] [Full Text] [Related]

  • 5. Interactions of olopatadine and selected antihistamines with model and natural membranes.
    Brockman HL, Momsen MM, Knudtson JR, Miller ST, Graff G, Yanni JM.
    Ocul Immunol Inflamm; 2003 Dec; 11(4):247-68. PubMed ID: 14704897
    [Abstract] [Full Text] [Related]

  • 6. Pharmacology of [3H]-pyrilamine binding and of the histamine-induced inositol phosphates generation, intracellular Ca2+ -mobilization and cytokine release from human corneal epithelial cells.
    Sharif NA, Wiernas TK, Griffin BW, Davis TL.
    Br J Pharmacol; 1998 Nov; 125(6):1336-44. PubMed ID: 9863665
    [Abstract] [Full Text] [Related]

  • 7. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.
    Kida T, Fujii A, Sakai O, Iemura M, Atsumi I, Wada T, Sakaki H.
    Exp Eye Res; 2010 Jul; 91(1):85-91. PubMed ID: 20412793
    [Abstract] [Full Text] [Related]

  • 8. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell.
    Leonardi A, Quintieri L.
    Expert Opin Pharmacother; 2010 Apr; 11(6):969-81. PubMed ID: 20307221
    [Abstract] [Full Text] [Related]

  • 9. Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells.
    Cook EB, Stahl JL, Barney NP, Graziano FM.
    Ann Allergy Asthma Immunol; 2001 Nov; 87(5):424-9. PubMed ID: 11730187
    [Abstract] [Full Text] [Related]

  • 10. The noncompetitive antagonism of histamine H1 receptors expressed in Chinese hamster ovary cells by olopatadine hydrochloride: its potency and molecular mechanism.
    Matsumoto Y, Funahashi J, Mori K, Hayashi K, Yano H.
    Pharmacology; 2008 Nov; 81(3):266-74. PubMed ID: 18268402
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs.
    Yanni JM, Weimer LK, Sharif NA, Xu SX, Gamache DA, Spellman JM.
    Arch Ophthalmol; 1999 May; 117(5):643-7. PubMed ID: 10326962
    [Abstract] [Full Text] [Related]

  • 12. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research.
    Rosenwasser LJ, O'Brien T, Weyne J.
    Curr Med Res Opin; 2005 Sep; 21(9):1377-87. PubMed ID: 16197656
    [Abstract] [Full Text] [Related]

  • 13. Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug.
    Ohmori K, Hasegawa K, Tamura T, Miyake K, Matsubara M, Masaki S, Karasawa A, Urayama N, Horikoshi K, Kajita J, Hasegawa M, Taniguchi K, Komada T, Kawamoto Y.
    Arzneimittelforschung; 2004 Sep; 54(12):809-29. PubMed ID: 15646365
    [Abstract] [Full Text] [Related]

  • 14. Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo.
    Galatowicz G, Ajayi Y, Stern ME, Calder VL.
    Clin Exp Allergy; 2007 Nov; 37(11):1648-56. PubMed ID: 17877767
    [Abstract] [Full Text] [Related]

  • 15. Olopatadine inhibits TNFalpha release from human conjunctival mast cells.
    Cook EB, Stahl JL, Barney NP, Graziano FM.
    Ann Allergy Asthma Immunol; 2000 May; 84(5):504-8. PubMed ID: 10831003
    [Abstract] [Full Text] [Related]

  • 16. Emedastine: a potent, high affinity histamine H1-receptor-selective antagonist for ocular use: receptor binding and second messenger studies.
    Sharif NA, Su SX, Yanni JM.
    J Ocul Pharmacol; 1994 May; 10(4):653-64. PubMed ID: 7714409
    [Abstract] [Full Text] [Related]

  • 17. Azelastine's inhibition of histamine and tryptase release from human umbilical cord blood-derived cultured mast cells as well as rat skin mast cell-induced vascular permeability: comparison with olopatadine.
    Lytinas M, Kempuraj D, Huang M, Kandere K, Boucher W, Letourneau R, Jeudy S, Fitzgerald K, Spear K, Athanasiou A, Theoharides TC.
    Allergy Asthma Proc; 2002 May; 23(1):45-51. PubMed ID: 11894734
    [Abstract] [Full Text] [Related]

  • 18. Azelastine is more potent than olopatadine n inhibiting interleukin-6 and tryptase release from human umbilical cord blood-derived cultured mast cells.
    Kempuraj D, Huang M, Kandere K, Boucher W, Letourneau R, Jeudy S, Fitzgerald K, Spear K, Athanasiou A, Theoharides TC.
    Ann Allergy Asthma Immunol; 2002 May; 88(5):501-6. PubMed ID: 12027072
    [Abstract] [Full Text] [Related]

  • 19. Ophthalmic antihistamines and H1-H4 receptors.
    Wade L, Bielory L, Rudner S.
    Curr Opin Allergy Clin Immunol; 2012 Oct; 12(5):510-6. PubMed ID: 22918191
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
    Avunduk AM, Tekelioglu Y, Turk A, Akyol N.
    Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.